Total
0
Shares
Azure Healthcare’s (ASX:AZV) subsidiary wins $1.6M contract
  • Azure Healthcare's (AZV) subsidiary, Austco Canada, has been awarded a $1.6 million contract to supply its Tacera Nurse Call platform to a new 350 bed hospital
  • The contract was from building and construction company EllisDon who are building the hospital
  • Austco's technology will be integrated with EllisDon's technology which will enhance communication between patients and caregivers
  • The new hospital is expected to be completed in 2023
  • On market close for the day, Azure is down 3.23 per cent and is trading for 9 cents per share.

Azure Healthcare's (AZV) subsidiary, Austco Canada, has received $1.6 million contract to supply its Tacera Nurse Call platform to a new 350 bed hospital.

The technology enables nurse call alarms to be monitored with alarm and response data then collected to measure the performance outcomes.

Austco Canada was picked by construction and building services company EllisDon as its software is the most flexible and advanced.

The new hospital is currently construction and is expected to be completed in 2023, with the Austco Tacera system expected to be delivered in 2022.

All beds will feature the Austco Patient System which will be integrated with EllisDon’s Building Management System. Both systems will enhance communication between patients and caregivers.

"We are committed to providing innovative solutions that deliver quality care and optimise the patient experience," Austco CEO Clayton Astles said.

"Our exceptional Tacera nurse call system is integral to quality operation of any hospital and our technology drives productivity and ensures improvement in patient care," he added.

On market close for the day, Azure is down 3.23 per cent and is trading for 9 cents per share.


Subscribe


AZV by the numbers
More From The Market Herald
Factor Therapeutics (ASX:FTT) pulls out of LONGMILE transaction

" Factor Therapeutics (ASX:FTT) pulls out of LONGMILE transaction

Biotechnology company Factor Therapeutics (FTT) has cancelled its proposed transaction with LONGMILE Veterinary PET Imaging.
Prescient Therapeutics (ASX:PTX) - CEO & Managing Director, Steven Yatomi - The Market Herald

" Prescient Therapeutics (ASX:PTX) to begin three next-gen CAR T programs

Prescient Therapeutics (PTX) has announced three internal development programs for its immune receptor technology platform, OmniCAR.
Cyclopharm (ASX:CYC) - Managing Director and CEO, James McBrayer (right) - The Market Herald

" Cyclopharm (ASX:CYC) progresses U.S. FDA approval for Technegas

Cyclopharm (CYC) has announced its Technegas product is on track to receive United States Food and Drug Administration (FDA) approval in the first
Orthocell (ASX:OCC) - Managing Director, Paul Anderson - The Market Herald

" U.S. FDA clears Orthocell’s (ASX:OCC) CelGro product

Orthocell (OCC) has received Food and Drug Administration (FDA) 501K approval to supply and market its medical collagen product CelGro in the U.S.